Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6485418 | 0.86 | ALDH1A1 (0.50) | MAPTALDH1A1LMNATHRBTDP1 | |
| SCHEMBL5462316 | 0.85 | MAPT (0.39) | MAPTALDH1A1LMNATHRBTDP1 | |
| SCHEMBL6478544 | 0.85 | MAPT (0.39) | MAPTALDH1A1LMNATHRBTDP1 | |
| SCHEMBL5742748 | 0.85 | MAPT (0.39) | MAPTALDH1A1LMNATHRBTDP1 | |
| SCHEMBL6491940 | 0.83 | MAPT (0.48) | MAPTALDH1A1LMNATDP1KMT2A | |
| SCHEMBL31639877 | 0.81 | ALDH1A1 (0.44) | MAPTALDH1A1LMNATHRBKMT2A | |
| SCHEMBL6476736 | 0.80 | MAPT (0.58) | MAPTALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL6478813 | 0.77 | ALDH1A1 (0.38) | MAPTALDH1A1LMNATHRBTDP1 | |
| SCHEMBL25172775 | 0.77 | FFAR4 (0.45) | MAPTALDH1A1LMNATDP1 | |
| SCHEMBL2448576 | 0.77 | MAPT (0.64) | MAPTALDH1A1LMNATHRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6875784-B2 | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040127530-A1 | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127530-A1 | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives | OXA1L, CYP1B1, MT-CO1 | MAPT 2671/4885ALDH1A1 345/4885LMNA 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.